Akebia Therapeutics, Inc. (FRA:AX9)

Akebia Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-15.91	-69.41	-51.93	-94.23	-282.02	-384.84
Depreciation & Amortization	14.49	41.7	41.85	37.7	37.97	34.69
Loss (Gain) From Sale of Assets	-0.17	-	-	-	-	-
Asset Writedown & Restructuring Costs	-	-	0.78	8.77	-	114.43
Loss (Gain) From Sale of Investments	-	-	-	-	-0.02	-0.05
Stock-Based Compensation	9.78	7.78	9.32	17.85	22.74	24.46
Provision & Write-off of Bad Debts	2.26	0.88	-	-	-	-
Other Operating Activities	30.57	18.07	-2.68	-41.8	73.98	113.78
Change in Accounts Receivable	-36.31	4.05	0.99	11.3	-24.03	11.67
Change in Inventory	-14.2	-28.4	-2.54	19.09	-24.95	6.16
Change in Accounts Payable	-4.94	-1.36	-5.24	1.5	-11.74	3.68
Change in Unearned Revenue	3.88	-	-3.74	4.65	1.82	-32.39
Change in Other Net Operating Assets	42.95	-13.96	-10.2	-37.98	-46.72	-1.97
Operating Cash Flow	32.4	-40.66	-23.38	-73.15	-252.97	-110.39
Capital Expenditures	-0.22	-0.03	-	-0.11	-0.06	-0.32
Investment in Securities	-	-	-	-	40	-39.69
Investing Cash Flow	-0.05	-0.03	-	-0.11	39.94	-40
Long-Term Debt Issued	-	45	-	-	-	19.98
Long-Term Debt Repaid	-	-37.1	-32	-33	-	-
Net Debt Issued (Repaid)	9.54	7.9	-32	-33	-	19.98
Issuance of Common Stock	90.62	43.03	6.79	7.6	88.95	211.75
Other Financing Activities	-0.06	-1.27	-	40	44.78	-
Financing Cash Flow	100.1	49.66	-25.21	14.6	133.73	231.72
Net Cash Flow	132.45	8.97	-48.59	-58.67	-79.29	81.33
Free Cash Flow	32.17	-40.69	-23.38	-73.27	-253.02	-110.71
Free Cash Flow Margin	14.29%	-25.40%	-12.02%	-25.05%	-119.55%	-37.57%
Free Cash Flow Per Share	0.13	-0.19	-0.13	-0.40	-1.52	-0.80
Cash Interest Paid	5.04	5.04	6.06	6.76	9.63	7.84
Levered Free Cash Flow	50.71	17.83	22.11	-15.3	-136.04	-17.99
Unlevered Free Cash Flow	67.1	29.2	25.88	-5.5	-123.53	-12.42
Change in Working Capital	-8.63	-39.68	-20.73	-1.44	-105.61	-12.86

Source: S&P Global Market Intelligence. Standard template. Financial Sources.